Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Womens HealthAWHL 35 Equity-to-Asset is -1.64 as of Jun. 2026. GuruFocus rates AWHL with a GF Score™ of 35/100 and a GF Value™ of $0.21 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Aspira Womens Health ranks worse than 95.26% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aspira Womens Health's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $-7.26 Mil. Aspira Womens Health's Total Assets for the quarter that ended in Jun. 2026 was $4.44 Mil.
Therefore, Aspira Womens Health's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was -1.64.
The historical rank and industry rank for Aspira Womens Health's Equity-to-Asset or its related term are showing as below:
AWHL'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.64 Med: 0.48 Max: 0.84
Current: -1.64
During the past 13 years, the highest Equity to Asset Ratio of Aspira Womens Health was 0.84. The lowest was -1.64. And the median was 0.48.
AWHL's Equity-to-Asset is ranked worse than 95.26% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs AWHL: -1.64
Aspira Womens Health (OTCPK:AWHL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aspira Womens Health Equity-to-Asset Related Terms
Aspira Womens Health Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AWHL vs MBAI, XWEL, ADVB: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Aspira Womens Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aspira Womens Health's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (AWHL) has a Equity-to-Asset of -1.64 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aspira Womens Health and its competitors. According to the industry distribution chart, Aspira Womens Health ranks #201 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 95.3%.
Is Aspira Womens Health's Equity-to-Asset too high?
Aspira Womens Health's current Equity-to-Asset is -1.64. Based on the distribution chart, Aspira Womens Health ranks #201 out of 211 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Aspira Womens Health has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Equity-to-Asset compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #201 out of 211 companies for Equity-to-Asset. This places Aspira Womens Health in the lower half of its industry. The industry median Equity-to-Asset is 0.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aspira Womens Health and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current Equity-to-Asset is -1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $0.27 — trading 28.6% above its estimated fair value. The current Equity-to-Asset is -1.64. Aspira Womens Health's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Equity-to-Asset is -1.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.27 is trading 28.6% above its estimated GF Value™ of $0.21.
GuruFocus considers Aspira Womens Health to be Modestly Overvalued.
Key valuation signals for AWHL:
Equity-to-Asset: -1.64
GF Value™: $0.21 vs. price of $0.27 (28.6% above fair value)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
35GF Score
Get the complete analysis for AWHL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
